The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sandonorm     [1-[(2-methyl-1H-indol-4- yl)oxy]-3-(tert...

Synonyms: Wandonorm, BOPINDOLOL, Bopindololum, Sandonorm (TN), SureCN49500, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BOPINDOLOL


Psychiatry related information on BOPINDOLOL

  • Bopindolol satisfactorily modifies not only resting but also exercise BP during isometric and isotonic load, thus reducing BP fluctuation during physical activities of the hypertensive patient [6].

High impact information on BOPINDOLOL


Chemical compound and disease context of BOPINDOLOL


Biological context of BOPINDOLOL


Anatomical context of BOPINDOLOL

  • Haemodynamic effects of bopindolol and atenolol in coronary artery disease. A noninvasive study [14].
  • We conclude that bopindolol protects the myocardium against ischaemia and that the effect lasts for at least 24 h when therapy is given once daily [15].
  • The pKi values of bopindolol and its two metabolites for beta 2-adrenoceptors in the bovine mesenteric artery were 7.70 +/- 0.13, 8.07 +/- 0.13, 8.20 +/- 0.24, respectively, with 20-785 showing the highest values among these drugs [16].
  • In contrast, the results from pharmacological assessment for antagonistic potencies, using atria and trachea, showed that bopindolol and its two metabolites did not have significant selectivity on beta 1- and beta 2-adrenoceptors [17].
  • These findings suggest that bopindolol had a beneficial effect on beta-adrenoceptors in the membranes of cardiac muscles of SHR, implying that these effects may contribute to lowering hypertension [18].

Associations of BOPINDOLOL with other chemical compounds

  • The effects of bopindolol or metoprolol on BP and heart rate were similar: return to normal values was achieved in 70% of patients with either drug [6].
  • 8. Blood flow in the brown fat was markedly increased by carvedilol and bopindolol, but not by celiprolol and propranolol [19].
  • Thirty-five hypertensive patients with LVH and supine diastolic blood pressures (DBPs) greater than or equal to 100 and less than or equal to 120 mm Hg received increasing doses of isradipine (1.25, 2.5, and 5 mg twice daily); if blood pressure was not controlled, bopindolol (0.5-2 mg once daily) was added to the treatment [10].
  • The first study described here was carried out to define the role of a genetic determinant (debrisoquine-type oxidation polymorphism) on plasma concentration of bopindolol and its pharmacological effect [20].
  • The generation of singlet molecular oxygen ((1)O(2)) and hydroxyl radicals (HO*) during peroxidation of bopindolol in the presence of Co(II) ions was studied using electron spin resonance (ESR) and spectrophotometry methods [21].

Gene context of BOPINDOLOL

  • The platelet count, the plasma levels of 6-oxo-PGF1 alpha, beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) were not affected by bopindolol [13].
  • It is suggested that (+/-)- and (-)-pindolol, mepindolol and bopindolol may be slowly dissociating beta 1-adrenoreceptor antagonists [22].
  • Bopindolol caused a significant attenuation of the rise in plasma renin activity produced by passive head-up tilting to 75-85 degrees [23].
  • After bopindolol withdrawal there was, in contrast, an overshoot of plasma prolactin and a persistent elevation of plasma potassium and adrenaline post-isoprenaline [24].
  • Following bopindolol administration GFR, RPF, and filtration fraction remained stable, in spite of a fall of DBP from 80 +/- 7 to 76 +/- 4 and to 72 +/- 9 mm Hg in normotensives (p less than 0.05) and from 106 +/- 11-96 +/- 10 and to 91 +/- 8 mm Hg in hypertensives (p less than 0.05) on D1 and D21, respectively [25].

Analytical, diagnostic and therapeutic context of BOPINDOLOL

  • Plasma concentrations determined using a radio-receptor assay (RRA) and high pressure liquid chromatography (h.p.l.c.) yielded almost identical results, indicating that hydrolysed bopindolol, the major metabolite, is responsible for the pharmacological activity of the drug [26].
  • This article describes the development of an analytical procedure and presents a reversed-phase HPLC method with coulometric detection suitable for plasma analyses during pharmacokinetic investigations of bopindolol therapy [27].
  • Scintigraphic ventriculography combined with an exercise test was carried out at baseline before treatment with bopindolol, and repeated after 7 and 14 days treatment [15].
  • Determination of bopindolol in pharmaceuticals by capillary isotachophoresis [28].
  • To determine the optimal antihypertensive dose of bopindolol, we performed a randomized double-blind study in parallel groups [29].


  1. The clinical pharmacology of bopindolol, a new long-acting beta-adrenoceptor antagonist, in hypertension. van den Meiracker, A.H., Man in 't Veld, A.J., van Eck, H.J., Boomsma, F., Derkx, F.H., Mulder, P., Schalekamp, M.A. Clin. Pharmacol. Ther. (1987) [Pubmed]
  2. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Harron, D.W., Goa, K.L., Langtry, H.D. Drugs (1991) [Pubmed]
  3. Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action. Carboni, G.P., Scardovi, A.B., D'Ermo, M., Prati, P.L. British journal of clinical pharmacology. (1991) [Pubmed]
  4. Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity. Aellig, W.H. British journal of clinical pharmacology. (1985) [Pubmed]
  5. The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol. MacDonald, N.J., Grant, A.C., Rodger, R.S., Meredith, P.A., Elliott, H.L. British journal of clinical pharmacology. (1991) [Pubmed]
  6. Bopindolol: Czechoslovak experience with a new beta blocker in the treatment of hypertension. Widimský, J., Lefflerová, K., Dvorák, I., Fedelesová, V., Lupínek, Z., Mayer, O., Pinterová, E. Am. J. Cardiol. (1991) [Pubmed]
  7. Simultaneous modeling of bopindolol kinetics and dynamics. Platzer, R., Galeazzi, R.L., Niederberger, W., Rosenthaler, J. Clin. Pharmacol. Ther. (1984) [Pubmed]
  8. Dose-finding study with bopindolol in arterial hypertension. Willimann, P., Peter, R., Siegenthaler, H. J. Cardiovasc. Pharmacol. (1986) [Pubmed]
  9. Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Schiess, W., Welzel, D., Gugler, R. Eur. J. Clin. Pharmacol. (1984) [Pubmed]
  10. Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine. Török, E., Borbás, S., Lengyel, M., Zorándi, A. J. Cardiovasc. Pharmacol. (1992) [Pubmed]
  11. Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. Wensing, G., Branch, R.A., Humbert, H., Ohnhaus, E.E., Kirch, W. Eur. J. Clin. Pharmacol. (1990) [Pubmed]
  12. Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients. Van Brummelen, P., Bolli, P., Koolen, M.I., Staehelin, H.B., Bühler, F.R. British journal of clinical pharmacology. (1984) [Pubmed]
  13. Effects of bopindolol on platelet function in hypertension at rest and during exercise. Virgolini, I., Fitscha, P., Rauscha, F., Sinzinger, H. Prostaglandins Leukot. Essent. Fatty Acids (1990) [Pubmed]
  14. Haemodynamic effects of bopindolol and atenolol in coronary artery disease. A noninvasive study. Rapola, J.M., Pellinen, T.J., Toivonen, L., Nieminen, M.S. Ann. Med. (1990) [Pubmed]
  15. Effects of bopindolol on left ventricular function during exercise in patients with coronary artery disease. Righetti, A., Mérier, G., Viquerat, C., Ratib, O., Rutishauser, W. J. Cardiovasc. Pharmacol. (1986) [Pubmed]
  16. The affinity of bopindolol and its two metabolites for a beta 2-adrenoceptor in the bovine mesenteric artery. Hosohata, Y., Suzuki, M., Karakisawa, Y., Maruyama, K., Nagatomo, T. Biol. Pharm. Bull. (1994) [Pubmed]
  17. Beta-blocking potency and selectivity of bopindolol and its two metabolites for beta 1- and beta 2-adrenergic receptors as assessed by radioligand binding assay. Sakuma, N., Tsuchihashi, H., Hosohata, Y., Akashi, H., Kinami, J., Nagatomo, T. J. Pharmacobio-dyn. (1991) [Pubmed]
  18. Effects of chronic administration of bopindolol on the binding characteristics of cardiac alpha 1H-, alpha 1L-, beta 1- and beta 2-adrenoceptor subtypes in cardiac muscles of spontaneously hypertensive rats (SHR). Hosohata, Y., Sasaki, K., Maruyama, K., Ohnuki, T., Hattori, K., Suzuki, J., Watanabe, K., Nagatomo, T. Biol. Pharm. Bull. (1996) [Pubmed]
  19. Effect of vasodilatory beta-adrenoceptor blockers on cardiovascular haemodynamics in anaesthetized rats. Takahashi, H., Masaki, H., Komiyama, Y., Masuda, M., Nishimura, M. Clin. Exp. Pharmacol. Physiol. (2002) [Pubmed]
  20. Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers. Dayer, P., Mérier, G., Perrenoud, J.J., Marmy, A., Leemann, T. J. Cardiovasc. Pharmacol. (1986) [Pubmed]
  21. Spin trapping study of reactive oxygen species formation during bopindolol peroxidation. Kruk, I., Michalska, T., Kladna, A., Aboul-Enein, H.Y. Biopolymers (2002) [Pubmed]
  22. The effects of beta-adrenoreceptor antagonists on the force responses of the electrically driven rat right ventricle strip to isoprenaline. Doggrell, S.A. Journal of autonomic pharmacology. (1989) [Pubmed]
  23. Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tilting. Turner, D.R., Goodwin, F.J., Knight, A.R., Littlejohns, D.W., Sharman, V.L., Vere, D.W. British journal of clinical pharmacology. (1984) [Pubmed]
  24. Withdrawal phenomena after atenolol and bopindolol: hormonal changes in normal volunteers. Walden, R.J., Tomlinson, B., Graham, B., Smith, C., Betteridge, D.J., Prichard, B.N. British journal of clinical pharmacology. (1990) [Pubmed]
  25. Effects of bopindolol on renal function. Fabre, J., Wintsch, J., Peter-Contesse, R., Bouchardy, C., Liniger, C., Favre, L., Donath, A. J. Cardiovasc. Pharmacol. (1986) [Pubmed]
  26. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. Aellig, W.H., Nüesch, E., Engel, G., Grevel, J., Niederberger, W., Rosenthaler, J. British journal of clinical pharmacology. (1986) [Pubmed]
  27. Analytical problems encountered during high-performance liquid chromatographic separation and coulometric detection of bopindolol metabolites in human plasma. Perkins, S.L., Tattrie, B., Johnson, P.M., Rabin, E.Z. Therapeutic drug monitoring. (1988) [Pubmed]
  28. Determination of bopindolol in pharmaceuticals by capillary isotachophoresis. Urbánek, M., Pospísilová, M., Polásek, M. Journal of pharmaceutical and biomedical analysis. (2002) [Pubmed]
  29. Bopindolol in the treatment of moderate hypertension: a dose-response study. Moleur, P., Peyrieux, J.C., Luciani, J., David, D., Boissel, J.P. Fundamental & clinical pharmacology. (1988) [Pubmed]
WikiGenes - Universities